CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

PR Newswire Biotech
Original article

Nektar Therapeutics Announces Pricing of Upsized $325 Million Public Offering

Neutral
AI Analysis

Summary

Nektar Therapeutics announced the pricing of an upsized underwritten public offering of $325 million. The company is a clinical-stage biotechnology firm focused on immunotherapy drug development.

Importance:6/10
Sentiment:
0.00
public offeringcapital raiseimmunotherapyupsized offering
Related Companies

Read the original article

Published by PR Newswire Biotech on April 22, 2026 1:30 AM

Read Original